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Cystic Fibrosis (CF) is the most common autosomal recessive disorder among Caucasians 
caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, which encodes a 
protein localized in the apical plasma membrane (PM) of epithelial cells that functions as a chloride (Cl-
) and bicarbonate (HCO3-) channel. 
Previous studies have shown the occurrence of at least one CFTR mutation also in non-CF 
patients with asthma, chronic bronchiectasis and chronic obstruction pulmonary disease (COPD) with 
unknown etiopathology. 
Until now about 2,000 CFTR variations have been found, in which 11% of them are known to 
be splicing mutations. A novel antisense oligonucleotide (AON) therapy approach corrects splicing 
defects and is giving some hope for patients carrying this type of mutations. 
The objective of the current MSc project was two-fold, namely: 
1) To investigate the possible involvement of the 9 most common Portuguese CFTR 
mutations in causing non-CF respiratory disorders: asthma, COPD and chronic 
bronchiectasis. 
2) To characterize the impact of four splicing mutations located in the same splicing 
consensus-711+1G>T, 711+3A>T, 711+3A>G and 711+5G>A and correct them using a 
single AON. 
Our results showed that at least 3 mutations out of 9 most common Portuguese CFTR mutations 
were found in our cohort of patients with respiratory disorders. 
Concerning the study of splicing mutations, in vitro experiments were performed using a 
reporter splicing minigene. We showed that all four splicing mutations located in the same splicing 
consensus one IVS5 caused skipping of exon 5, which produce a smaller protein and lead to a 
mislocalization of the CFTR protein in the PM. In addition, the same AON potentially corrected all four 
splicing mutations. 
Altogether these data suggest that there is an involvement of some CFTR mutations commonly 
found in Portugal in causing non-CF chronic airway diseases and that patients carrying the splicing 

























A fibrose quística (FQ) é a doença autossómica recessiva mais comum na população 
Caucasiana, afetando 1 em cada 6000 portugueses. Esta doença afeta vários órgãos e os doentes 
apresentam variados sintomas, os mais comuns sendo: elevadas concentrações de cloreto no suor, 
infeções bacterianas recorrentes devido ao muco espesso formado nos pulmões e malnutrição. A FQ é 
causada por mutações no gene da CFTR (do inglês Cystic fibrosis transmembrane conductance 
regulator) que codifica uma glicoproteína localizada na membrana apical de células epiteliais e funciona 
como um canal de cloreto (Cl-) e bicarbonato (HCO3-). 
Tradicionalmente, o diagnóstico da FQ baseia-se nas manifestações clínicas, história familiar e 
dois testes de suor positivos (>60mM), porém quando esta abordagem é inconclusiva, são feitos testes 
genéticos para identificar mutações nos dois alelos e medições de corrente para verificar a função ou 
disfunção da CFTR. 
Estudos prévios reportaram uma parcial disfunção da proteína CFTR em doentes sem nenhuma 
manifestação clínica de FQ, mas com outras doenças como pancreatite, asma, bronquiectasias crónicas 
e doenças pulmonares de obstrução crónica (DPCO), de origem desconhecida, sugerindo uma 
associação entre mutações no gene da CFTR e outras doenças que não sejam FQ. Adicionalmente, foi 
demonstrado que alguns desses indivíduos possuíam apenas uma mutação no gene da CFTR. Contudo, 
as mutações encontradas são raras e portanto não incluídas entre as mutações mais frequentes 
encontradas em Portugal. Além disso nem todas as variantes na CFTR estão descritas como causadoras 
de FQ. 
Atualmente são conhecidas mais de 2.000 variações no gene da CFTR, e apenas 
aproximadamente 250 mutações estão descritas como sendo causadoras de FQ. Estas mutações são 
classificadas de acordo com o defeito causado na proteína e estão agrupadas em sete classes (I-VII). As 
mutações de splicing pertencem à classe V (mutações que diminuem os níveis da proteína na membrana 
apical) e compreendem uma fração de 11% das variações conhecidas no gene da CFTR. Estas mutações 
resultam num splicing anormal destruindo as junções normais dos RNAs ou criando um novo local de 
splicing no interior de um intrão ou de um exão. Tais alterações levam à produção de uma proteína 
disfuncional ou truncada o que diminui os níveis da proteína normal que é expressa. 
É previsível que a percentagem de mutações de splicing sejam superiores a 11%, devido às 
mutações missense, que não estão totalmente caracterizadas e que também podem levar a um splicing 
anormal. Os doentes que possuem esta classe de mutações podem beneficiar apenas de um fármaco que 
potencia a função da proteína resultante de transcritos normais, o Ivacaftor (VX770). Porém, como 
algumas mutações de splicing diminuem drasticamente os níveis de proteína funcional, potenciar a 
proteína não é suficiente, sendo necessário corrigi-la. Para este efeito uma nova abordagem tem sido 
adotada nomeadamente, o uso de terapias de RNA que corrigem o defeito a nível do RNA mensageiro 
(mRNA). Uma dessas terapias é o uso de AONs (do inglês antissense oligonucleotides), que bloqueiam 
ou aumentam o processo de splicing, de acordo com a sequência a  que se ligarão. 
No presente trabalho de Mestrado tivemos dois objetivos principais, nomeadamente: 
1) Investigar o envolvimento das nove mutações do gene da CFTR mais comuns entre os 
Portugueses no desenvolvimento de doenças respiratórias, tais como asma, doença 
pulmonar obstrutiva crónica (DPOC) e bronquiectasias. 
2) Caracterizar o impacto de quatro mutações -711+1G>T, 711+3A>T, 711+3A>G e 
711+5G>A localizadas na mesma sequência de consensus do intrão 5 e finalmente corrigi-
las usando um único AON desenhado no nosso laboratório. 
Para o primeiro objetivo, foi extraído DNA genómico de amostras de sangue dos indivíduos em 
estudo e, com técnicas de PCR (do inglês polymerase chain reaction) modificado, foram procuradas as 




Os resultados mostram que três das nove mutações mais comuns foram encontradas em 
pacientes com doenças respiratórias, onde a mutação mais comum foi a F508del, a mais comum na 
população mundial. Adicionalmente constatou-se que a G576A, descrita como sendo um polimorfismo, 
também parece estar envolvida na suscetibilidade de aparecimento de doenças respiratórias mesmo 
quando presente individualmente, sem que o outro alelo do indivíduo esteja mutado, porém este 
polimorfismo não foi encontrado entre a população FQ. Estes resultados sugerem que os polimorfismos 
no gene da CFTR podem estar envolvidas no aparecimento de asma, bronchiectasias e DPCO, e ainda 
que mutações num só alelo deste gene podem aumentar a suscetibilidade de um indivíduo portador 
desenvolver doenças respiratórias, sem que haja manifestação clínica típica de FQ. 
Para o 2º objetivo, utilizámos um mini-gene de CFTR consistindo num construto de cDNA de 
wt-CFTR previamente clonado no plasmídeo pcDNA5, contendo dois intrões: o intrão quatro (IVS4) e 
o intrão cinco (IVS5) entre os exões 4 e 5 e os exões 5 e 6a, respetivamente, e dois marcadores (eGFP 
em N-terminal e Flag-tag no 4º loop extracelular) . Introduzimos cada uma das mutações de splicing em 
estudo por mutagénese direcionada neste mini-gene repórter. De seguida, cada um dos construtos foi 
clonado num vetor lentiviral para a produção de novas linhas celulares (experiência por concluir para 
comparação de resultados). Toda a caracterização apresentada ao longo deste trabalho, foi feita em 
células que expressavam cada um dos construtos por transfeção transitória. O impacto de cada mutação 
expressa pelas células foi caracterizado a nível do mRNA, expressão e localização da proteína na 
membrana. Resultados de PCR quantitativo (qPCR) e semi-quantitativo revelaram que as quatro 
mutações provocam a remoção total do exão cinco e que a mutações 711+1G>T e 711+5G>A diminuem 
drasticamente os níveis de transcritos normais, mais do que as mutações 711+3A> G e 711+3A>T. Com 
a técnica de Western blot (WB) verificou-se que a proteína resultante dos construtos com as mutações 
711+1G>T, 711+3A>T, 711+3A>G e 711+5G>A é menor do que a proteína normal. Para além disso, 
quando caracterizadas por imunofluorescência, notou-se uma redução drástica dessas proteínas na 
membrana plasmática (PM), sugerindo um défice no processamento e possivelmente no tráfego da 
mesma. Na tentativa de corrigir todas as quatro mutações com o mesmo AON, este foi desenhado à 
distância de 20 bases a jusante do primeiro nucleótido do intrão 5, e verificou-se que um único AON 
aumentou o nível de transcritos normais produzidos e a expressão da proteína na PM. 
Na sua globalidade, os resultados obtidos ao longo deste trabalho indicam que as mutações no 
gene da CFTR mais comuns encontradas entre portugueses poderão estar envolvidas no 
desenvolvimento de doenças respiratórias sem que haja manifestação clínica de FQ, e ainda que um 
único AON pode beneficiar pacientes com pelo menos uma das mutações estudadas. 
Estudos futuros, expandindo a lista das mutações no gene da CFTR de pacientes com doenças 
respiratórias são importantes para potenciar e comprovar a associação entre a proteína CFTR e essas 
doenças. Além disso a determinação do genótipo e a caracterização do efeito das mutações ajudará a 
relacionar o genótipo com o fenótipo, melhorando assim o prognóstico tanto de pacientes com FQ como 
também a avaliação da suscetibilidade de um indivíduo portador desenvolver outras doenças 
respiratórias.   
A correção das mutações de splicing em estudo por este AON precisa ainda de ser avaliada em 
sistemas celulares derivados de materiais de doentes ex vivo para tornar os resultados mais robustos e 
fisiologicamente relevantes. Com efeito são já extremamente encorajadores e comprovar em materias 
de pacientes a eficácia dum mesmo AON para corrigir 4 mutações de splicing diferentes, aumentará a 
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Section I: Introduction  
1.1. Cystic Fibrosis (CF) and CF Diagnosis 
Cystic Fibrosis (CF) is the most common autosomal recessive disorder among Caucasians, 
affecting about 75,000 individuals worldwide, around 32,000 individuals in Europe and approximately 
300 individuals in Portugal with an estimated incidence of 1:6000 individuals in Portugal.1,2 In medieval 
folklore, infants with salty skin, were considered “bewitched” because they died at an early age. 
Nowadays it is known that these infants had CF.3 
The frequency of this disorder is highly variable and is often a function of ethnic and geographic 
origin of the affected patients.4 
CF is an inherited life-threatening disease, and it is caused by mutations in a single gene, the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which encodes CFTR protein, a 
chloride and bicarbonate channel responsible for regulation of ion transport across the apical membrane 
at the surface of certain epithelia.5–7 The hallmark of the mutational spectrum in the CFTR gene is the 
very high frequency of the F508del mutation in the Caucasian population, responsible for about two-
thirds of all CF chromosomes.8  
Clinically this disease is characterized by elevated levels of Cl- in sweat, meconium ileus, 
pancreatic insufficiency (PI), low body-mass index (BMI), infertility in males mostly because of 
bilateral absence of vas deferens (CBAVD), and undescended testicles or hydrocele, amenorrhea in 
females, severe nutritional and pulmonary involvement.3,6,7,9Furthermore, patients have a chronic or a 
recurrent cough, producing mucoid and purulent sputum. Recurrent wheezing and pneumonia, digital 
clubbing, nasal polyposis and sinusitis may also occur as CF manifestations.10,11  
In summary, CF is a multi-organ disorder. However, the dominant cause of morbidity and 
mortality is lung disease. There is a significant variability of CF symptoms among different patients, 
thus posing some difficulties in the clinical diagnosis.12 
 
Diagnosis 
The diagnosis of CF has traditionally relied on recognition of characteristic clinical symptoms 
and a family history of CF.12 However, to confirm a diagnosis of CF evidence of CFTR dysfunction is 
required. Approaches to demonstrate the latter include: (i) two consecutive sweat tests showing a high 
Cl-concentration in sweat (≥60mmol/L) (ii) two CFTR mutations previously described as CF-causing 
(mutations which are undefined or defined as a "mutation of varying clinical consequence" (MVCC), 
are not valid to confirm a diagnosis of CF); (iii) abnormal transepithelial Nasal Potential Difference 
(NPD) measurements; or (iv) absence or defective CFTR function determined in native colonic 
epithelium.13–15 Although each test mentioned above is recommended, there is no need to perform them 
all. Thus, a diagnosis of CF can be hierarchically established (see Fig 1.1), being the sweat Cl- the first 
one, secondly CFTR genetic analysis, and finally CFTR physiologic tests.16 Therefore, when the 
concentration of Cl- in sweat test is in the intermediate range (30-59mmol/L for infants less than six 





Figure 1.1 - Cystic Fibrosis Diagnosis Algorithm. The diagnosis of CF is firstly relied in clinical manifestations 
and in newborn screen results, secondly, it is necessary to have two positive sweat tests and finally two known CFTR 
mutations. If the results of sweat tests are inconclusive, for instance, borderline results, and if it is found only one CFTR 
mutation it is necessary to re-evaluate the results and perform functional assays. [Figure from MD Amaral, included with 
permission] 
 
Several kits to detect CFTR mutations are commercially available (using a discrete group of 
mutations, with the 50 most frequent mutation of each region), and they are advantageous because are  
fast and relatively cheap, which will detect 99% of affected individuals in the most populations.16–18 
Though these commercially available kits are limited because the diagnosis will be missed if patients 
carry mutations which are not included in the kit.16–20 To overcome this limitation, full CFTR gene 
sequencing is recommended, and it will detect most CFTR mutations, but, it may also detect novel 
mutations with unknown functional effect and undetermined CF disease prognosis. If such, it is 
necessary to confirm the CFTR (dys)function by electrophysiologic tests such as NPD and 
measurements of CFTR-mediated Cl- currents in colonic epithelial tissue (rectal biopsies).7,12,13,16 In 
addition, it is important to identify CFTR mutations in CF patients with none or just one mutation 
previously identified using other approaches such as for example DNA or mRNA analyse (routine 
technique used in our laboratory) and to characterize their effects ex vivo and in vitro, to establish better 
the diagnosis and prognosis of the CF disease. 
Recently the prenatal population screening for maternal CF carrier status and the newborn 
screening (NBS) have been widely used in the USA and Europe, which is helpful because early 
diagnosis and treatment reduce symptoms, improve health, and lower costs associated with disease 
complications.12 In Portugal NBS consists in a 1st test for immunoreactive trypsinogen (IRT), an assay 
for Pancreatitis-Associated Protein (PAP) in case of positive IRT, followed by a 2nd IRT and if all 
positive a final genetic analysis. All these strategies have resulted in increased life expectancy, as the 
predicted survival age of a CF patient in the past, was only six months,21 and now the predicted age is 
40 years old in the USA,2243.5 in the UK,23and 30.7 years old in Portugal according to CF adult follow-
up in specialized centres.24  
All these diagnosis methods have been advancing due to a better understanding of the CFTR 









1.2. CFTR: from Gene to Protein and Function 
CFTR gene and expression 
The CFTR gene was cloned in 1989 by using chromosome walking and jumping, and linkage 
disequilibrium studies.26 The gene comprises 27 coding exons (showed in figure 1.2) spanning over 
190Kb on the long arm of chromosome 7 (7q31.2), and the transcript is 6.5Kb.27  
The expression of CFTR is very complex and involves multiple tissue-specific transcriptions 
start sites, alternative first exons and alternatively spliced transcripts. The development, the pathologic 
conditions, the cell type and tissue, regulate the expression of CFTR. The sites of the CFTR expression 
are the epithelial surface throughout the body, such as submucosal glands, airways (the site of 
developmental regulation of CFTR expression), pancreas, the crypt in the intestinal tract, sweat glands, 
vas deferens, salivary glands.28,29   
The proper transcription of the CFTR gene gives rise a multi-domain glycoprotein of 1,480 
amino acids with a molecular weight of approximately 170 kDa. This protein belongs to the superfamily 
of the ATP-binding cassette (ABC) transporters.26,28,30It is composed by five domains, as shown in Fig. 
1.2: two transmembrane domains (TMD1 and TMD2, each comprising six transmembrane segments) 
which anchor the protein in the membrane and form the translocation pathway, two cytoplasmatic 
nucleotide binding domains (NBD1 and NBD2) which bind and hydrolyze ATP, and a central regulatory 
domain (RD).28,31,32  
 
Function 
The CFTR protein plays different roles according to its system/organ localization. For instance, 
in the intestine, pancreas and sweat gland secretory coil, CFTR plays a key role in fluids and electrolyte 
secretion, and in the sweat gland duct and the airway epithelia, it participates in fluid and electrolyte 
absorption.33 It functions as a Cl- and HCO3- channel  and it also works as a regulator of other channels, 
for instance, Epithelium Sodium (Na+) Channel (ENaC), that is downregulated by CFTR, potassium 
(K+) channels and outwardly rectifying Cl- channels (ORCCs),33–35 or as a tumour suppressor gene in 
the intestinal tract.36  
 
          
 Figure 1.2: Schematic representation of transcription, translation and localization of CFTR. The CFTR gene is 
composed by 27 coding exons overspanning 190Kb. When every intron are skipped during the transcription (maturation of 
mRNA), it has 6.5Kb. The proper translation, trafficking and folding give rise a multi-domain glycoprotein composed by five 
domains: two transmembrane domain (TMD1 and TMD2), two nucleotides binding domain (NBD1 and NBD2) and one 
regulatory domain (RD). Both C- and N- terminus are localized in the cytoplasm. It is also composed by six extracellular loops 





The production of defective CFTR protein results in abnormal transport of salt, not just due to 
abnormal Cl- but also due to an enhancement of  Na+ absorption, caused by ENaC upregulation thus 
causing a decrease in the water content and dehydration of epithelia of different organs, namely in the 
airways. This reduction causes thicker secretions in airway tract, which clog small airways, becoming a 
favourable environment for bacterial infections from the air (inhalation, for instance). Accumulation of 
the thick mucus leads to persistent infection and chronic inflammation. Because of chronic 
inflammation, the bronchi dilate, and their walls weaken, setting up bronchiectasis that results in further 
airflow obstruction. The cycle of airway obstruction, inflammation, and persistent infection leads to a 
progressive decline in lung function and eventually causes respiratory failure and lastly to death 
(Fig.1.3).37–39 
When CF was first described, the incidence of death among children in infancy or early 
childhood was very high. However, progresses in symptomatic therapies, such as mucolytics to dissolve 
the thick mucus, antibiotics to treat or prevent infections, anti-inflammatory agents to ameliorate chronic 
inflammation, pancreatic enzymes to compensate exocrine pancreatic insufficiency, fat-soluble vitamins 
and high caloric intake to overcome the deficiency of vitamins and  malabsorption of fats, respectively, 
have significantly improved the life expectancy of CF patients.6,10,27,40 
                      
Figure 1.3: Pathophysiologic cascade in Cystic Fibrosis that leads to lung disease, the main cause of high mortality 
rate among CF patients. Normally, CFTR proteins are located on the surface of the epithelial membrane and act as Cl- channels 
that in turn regulate the ENaC (epithelial sodium channel). The complex interplay of these channels regulates the 
electrochemical gradient that allows appropriate airway surface liquid depth and mucus viscosity. When the CFTR protein is 
defective or missing (caused by mutations in both alleles) it alters the ionic transports  (abnormal Cl- permeability and high rate 
of Na+ absorption into the cells), which leads to decrease of water content in the airway surface liquid, which in turn leads to 
production of viscous mucus. ENAC – Epithelium Sodium Channel Adapted from De Boeck & Amaral (2015)6 
 
1.3. CFTR mutations: classification according to their functional defect and class-specific 
therapies 
 Until now 2,019 variations have been found,41 with the following distributions: missense (39%); 
frameshift (16%); splicing (11%); nonsense (8%); large (3%) and in-frame (2%) deletions/ insertions; 
and promoter (1%); sequence variation (14%), unknown effect (6%).27,40,41 However, only about 250 
have been clearly defined as CF-causing, where approximately 20 mutations occur worldwide with 
frequency about 0.1% among CF patients, becoming very difficult to define the disease liability of such 
infrequent mutations.5,27,40,41  
 Although treatment advances over the past several decades have raised the median predicted 
survival age, the treatment costs of CF are very high, because of the amount of medicines taken daily 




Consequently, a new approach that corrects the basic defect of CF, in this case at the molecular level is 
needed. 
The basic defect in CF can be treated using small molecules to modulate defective CFTR protein 
and restore functional ion transport. There are already in the market compounds that restore CFTR 
trafficking and function such as, lumacaftor (VX809 – a corrector), ivacaftor (VX770 - potentiator), 
orkambi(VX809+VX770).43,44 Ivacaftor increases the time that CFTR channel is open, allowing Cl- ions 
to flow through the CFTR proteins on the surface of epithelial cells, and lumacaftor facilitate the 
trafficking of CFTR protein, thus allowing this protein to reach the membrane and transport Cl-.45–48 
However, these compounds do not restore all CFTR mutations currently described, being 
necessary a mutation-specific or mutation-class-specific approach to correct the protein defect. Indeed, 
CFTR mutations have been conventionally grouped into seven classes according to their functional 
defect (Figure 1.4):5,12,27,40,48,49  
❖ Class I mutations – result in no protein production, mostly nonsense or premature stop 
codon (PTC) mutations, which results in a truncated mRNA, leading to its degradation 
by nonsense-mediated decay (NMD), an mRNA surveillance mechanism. In this class, 
CFTR production could be obtained by using read through compounds to mask the PTC, 
leading to the NMD scape and allowing the cell to produce a full-length protein21,42. 
❖ Class II mutations – affect CFTR protein traffic to the correct cellular localization as a 
result of protein misfolding and retention in the endoplasmic reticulum (ER), resulting in 
premature degradation of the protein.50 The most common mutation, F508del belongs to 
this class. Small molecules, such as correctors can be used to correct this class of 
mutations, allowing the defective protein to reach the PM.46,51–53 Recently, Orkambi (a 
mix of XV809 and VX770) was approved by the Food and Drug Administration for some 
of the patients with this class of mutations.54  
❖ Class III mutations – lead to impaired gating of the CFTR channel, allowing the traffic 
of CFTR to the apical membrane, but causing poor regulation of the Cl- channel. They 
result in a very poorly functional protein. Potentiators, such as VX770 are used to increase 
the CFTR channel gating, enhancing then the Cl- transport.27 
❖ Class IV mutations – cause a significant decrease in CFTR channel conductance, 
notwithstanding the CFTR protein is present at the apical surface. Potentiators could 
improve the CFTR function.6,49,55  
❖ Class V mutations – lead to a major reduction of normal CFTR protein levels, mainly 
because of aberrant splicing. These mutations produce normal and aberrant mRNA and 
the proportion of mRNA variants may vary among patients in different organs of each 
patient. Patients with this class of mutations can beneficiate with potentiators that will 
enhance the function of the normal protein and RNA-based therapies that can enhance 
the normal mRNA production.49,56–58 Recently VX770 has been approved for some of this 
class of mutations.59 
❖ Class VI mutations – lead to a high turnover of CFTR at the cell surface, either by 
increasing CFTR endocytosis or by decreasing its recycling back to the cell surface. 
Stabilizers could be used for this class of mutations.6,27 
❖ Class VII mutations – lead to a non-functional and rescuable protein because of large 
deletions or insertions. Mutations in this class cannot be pharmacologically rescued, and 
therefore the promising therapies are Bypass therapies, i.e., by activating other alternative 




                 
 Figure 1.4: Classification of CFTR mutations accordingly their functional defect, and its potential target therapies. 
Adapted from 6 
 
 Patients with the same mutations have different responses to the same therapy, being crucial to 
study the response of these CFTR modulators in materials from each individual CF patients in a new 
strategy of personalised medicine. Thus primary cultures of human bronchial epithelial (HBE) cells and 
of nasal epithelial (HNE) cells as well as intestinal organoids produced from stem cells obtained from 
rectal biopsies directly from CF patients have been used as models for tests, such as measurements of 
the functional responses of CFTR and evaluation of drug efficacy.61,62 
 
1.4. Class V mutations: splicing mutations and correction by RNA-based therapies 
 Alternative splicing is not always deleterious, is a fundamental element in eukaryotic gene 
expression that increases the coding capacity to the human genome. However, if an intronic or exonic 
variant disrupts canonical splice motifs or creates a new cryptic splice site, it will lead to aberrantly 
spliced mRNAs, usually encoding nonfunctional proteins. These, however, do not always replace totally 
the normal protein expression, as often some levels of normal mRNA splicing also occur in parallel with 
the abnormal one.63–65 
 The splicing process is very complex, and several reactions are taken in place. The spliceosome, 
the major effector of the splicing reaction, is a complex of hundreds of interacting proteins and small 
nuclear RNAs (snRNAs) including the five small nuclear ribonucleoproteins (snRNPs) U1, U2, U4, U5 
and U6.66  
 First of all, U1 binds to the 5’ splice site (5´-ss) by complementarity and U2 binds to the branch 
point. The triple snRNPs (U4, U5 and U6) complex moves-in to associate with the assembling 
spliceosome. Then, the U4 leaves the complex, allowing the replacement of U1 by U6 that interacts with 
U2 to bring the branch point into proximity to the 5´-ss. At this point, the first transesterification reaction 
cleaves the 5'-ss of the intron of the downstream exon and attaches it to the branch point. U5 then brings 
the 3'-ss of the upstream exon and 5'-ss of the downstream exon into proximity with each other, allowing 
a second transesterification reaction that cleaves the 3'-ss of the upstream exon (as shown in Appendix 
1- Fig.1S). The splicing accuracy does not depend only on the mechanisms described above, but it also 
depends on more discrete elements, splicing regulatory elements which direct the splicing machinery to 
use the correct splice site. 66,67 
 Patients carrying one splicing (class V) mutation can have mild CF disease, and most of the times 
there are considered pancreatic sufficient (PS). It is reported that 11% of the CFTR variations are known 




higher because of the false missense mutations that have not been identified as causing abnormal 
splicing.40,68,69 In this way each nucleotide modification, including nonsense, missense and silent 
modifications, may potentially impact the splicing pattern, resulting in production of aberrant spliced 
transcripts.70 Thus, it becomes crucial to study splicing mutations, which allow a better understanding 
of splicing processes and the mechanism of disease-causing, which may help to develop the most 
relevant therapeutic strategy and thus contributing to the increase of life expectancy of patients carrying 
these class of mutations. 
 When the alteration is in the invariant donor splice site, +1, it is most likely that the correct spliced 
transcripts will strongly be reduced.53,71 
 For clarity, when it is referred to intronic splicing mutations, for example, 711+1G>T or 3272-
26A>G, the symbols "+" and "-" indicate nucleotides downstream and upstream of the exon/intron 
boundary, respectively. 
  
 RNA-based therapies 
 RNA-based therapies are therapies use RNA as a target to potentially tread diseases, caused by 
aberrant splicing. Targeting the RNA is an advantageous strategy because it avoids many of the risks 
and concerns associated with (DNA) gene therapy, such as random gene insertion. Furthermore, when 
an in vivo cellular basis is needed the presence within the cell of multiple different RNA processing 
pathways means that there is much scope for influencing its control at different levels. The dynamic 
nature of RNA turnover also implies that therapeutic interventions can be time-limited, dose titrated and 
modified according to response, adding further levels control.66 
 Novel therapeutic approaches to correct splicing mutations have been described using antisense 
oligonucleotides (AONs), that correct splicing defects, indicating that CF patients carrying such 
mutations may benefit from AON treatment.57 
 These AONs can be synthesised to be complementary and specific to a particular RNA sequence 
transcribed from the CFTR gene, meaning that only the RNA sequence of interest will be targeted. By 
designing AONs that bind to splice sites or to enhancer or silencer elements within the transcript, the 
splicing mechanism can be manipulated in a precise and reproducible way. Blocking splice sites and 
regulatory sequences prevents snRNPs and splicing factors such as SR proteins and hnRNPs from 
binding to the mutated site at the RNA transcript, allowing a directed exon skipping or inclusion, 
depending on the sequence blocked.72 
 Although RNA repair is transient and only modestly effective, studies of CFTR splicing 
polymorphisms suggest that 8% of normal CFTR message might be sufficient for normal lung function, 







1.5. Objectives of the present work 
This project had two main goals, namely: 
1) Firstly, to investigate the possible involvement of the CFTR in other respiratory diseases 
namely, COPD, DB and asthma. 
2) Secondly, to characterize the impact of four mutations localized in the same splicing consensus- 
711+1G>T, 711+3A>T, 711+3A>G and 711+5G>A and subsequently modulate them using an 
AON based strategy. 
 
To achieve these goals we proposed the following specific tasks: 
1.1. To screen non-CF individuals with other respiratory disorders for the most common CFTR 
mutations found in Portuguese CF patients. Control groups included: i) a group of patients 
known to have CF or suspicious of a CF diagnosis; ii) a group of carrier individuals; and iii) a 
group of healthy individuals with no respiratory phenotype. 
2.1. To generate cells lines expressing CFTR minigenes carrying the splicing mutations 711+1G>T, 
711+3A>G, 711+3A>T and 711+5G>A. 
2.2. To characterize the impact of four splicing mutations (711+1G>T, 711+3A>G, 711+3A>T and 
711+5G>A) at the mRNA, protein and functional levels. 
2.3. To use an AON strategy for modulation of the deleterious effect of these mutations at the 























Section II: Materials and Methods 
Part I: Methods to analyse patients’ materials 
2.1. The screen of mutations in CF and non-CF patients 
Before the studies, all individuals signed an informed consent. The patients’ materials in this 
study were irreversibly anonymised as stipulated in artº 19, in the Portuguese law 12/2005 from 26th of 
January. 
Initially, it was proposed to analyse the nine most common Portuguese CFTR mutations (panel 
obtained from World Health Organization (WHO), 2004 – shown in table 3.1) in individuals with 
suspicion of CF (who had two borderline sweat tests or just one identified mutation) and individuals 
with a CF familial history. However, for this study, the objective was extended to individuals who had 
two negative sweat tests and no CF familial history but have diagnosis of COPD, DB or asthma, to 
verify if the most common Portuguese CFTR mutations play a role in these respiratory diseases. It was 
also included healthy control, in order to discriminate better the CFTR sequence variation from CFTR 
mutations. 
 In order to achieve that, 249 Portuguese individuals divided into 4 four groups, namely, patients 
with suspicion of CF, individuals with CF sibling or with a CF familial history, non-CF with other 
respiratory diseases and healthy controls (individuals without a CF familial history, without clinical 
manifestations of any respiratory disease) were analysed. 
Genomic DNA (gDNA) was extracted from blood samples of 249 Portuguese individuals,  using 
the Wizard® Genomic DNA Purification kit following the manufacturers’ instructions performed by 
Verónica Felicio and further analysed for 9 most common CFTR mutations (table 3.1 ) extracted from 
a report of word Healthy Organizaton. 
The CFTR mutations were detected by Amplification Refractory Mutation System (ARMS), or 
Tetra-ARMS and Restriction fragment length polymorphism (RFLP) techniques, which were previously 
optimized in our laboratory. 
The ARMS technique is a simple, rapid and reliable method for the detection of any mutation 
involving single base changes or small deletions. This PCR modification consists of two complementary 
reactions. The first reaction contains an ARMS primer specific for the normal gDNA sequence and 
cannot amplify mutant DNA and the second one contains a mutant-specific primer and cannot amplify 
normal gDNA. The genotype of an individual can then be determined by analysis of the amplification 
products. An individual with no mutations generates a PCR product only in the normal reaction, an 
heterozygous individual gives products in both reactions, and a homozygous mutant individual does so 
only in the mutant reaction.75,76 
The tetra-ARMS technique is an ARMS modification using tetra-primers in the same reaction. Thus, 
the allele-specific amplification is achieved in a single PCR reaction using two outer primers and two 
allele-specific inner primers.77,78 Then PCR reactions were run on a 1%-3% agarose gel to confirm 
amplification and product pattern. Mutation detection was confirmed by sequencing.  
 
Part II: Methods to study splicing mutations in cellular systems 
2.2. Generation of models to study splicing mutations in IVS5 
2.2.1. Plasmid vectors 
A pcDNA5/FRT/eGFP/CFTR/IVS4art/IVS5/Flag mini-gene was previously constructed in our lab 
(the insert will be called here as eGFP/IVS4_5/wt/flag or the respective mutants). The construct carried 
a complete wildtype (wt) CFTR cDNA, containing an artificial intron 4 (IVS4art) with 351 nucleotides 
of the 5’ of the human IVS4 sequence joined with 351 nucleotides 3’ of the human IVS4 sequence 




inserted between exon 5 and exon 6a. It is also composed by eGFP in the N-terminal and flag in exon 
15 (4th extracellular loop), which was previously inserted in our lab. This mini-gene was then used to 
generate four splicing mutations (711+1G>T; 711+3A>T; 711+3A>G and 711+5G>A) by-site directed 
mutagenesis. 
Afterwards, each mini-gene was used to transiently transfect HEK293T cells and CFBE parental 
cells and was also used to stably transfect HEK FLP-In cells. The pcDNA5 mini-gene was also used to 
amplify the insert and clone into pLVX-puro to stably transfect CFBE parental cells. 
 
2.2.2. Site-directed mutagenesis 
Mutations on the same splicing consensus on IVS5 (711+1G>T, 711+3A>G, 711+3A>T and 
711+5G>A) were introduced into pcDNA5/FRT/eGFP/CFTR/IVS4art/IVS5/FLAG using the KOD Hot 
Start DNA Polymerase Protocol (Novagen). Where 10ng of plasmid were mixed with 1.5mM of MgSO4; 
1X of 10X Buffer for KOD Hot Start DNA Polymerase; 0.2µM of each dNTPs; 0.6µM of 
complementary pairs of mutagenic primers (described in Appendix 1 - Table 2); 0.02U/µl of KOD Hot 
Start DNA Polymerase and nuclease-free water to perform 50µl of reaction, using the PCR program 
described in Appendix 1 - Table 3. 
5µl of the reaction product were run by electrophorese in agarose 0.5% agarose gel to confirm the 
amplification of the plasmid. The PCR product was then incubated with DpnI (a restriction enzyme that 
hydrolyses methylated and hemimethylated DNA) for 1hour at 37ºC. After that, 200µl of competent 
bacteria were transformed with the hydrolysis product and grown on LB agar plates with 100µg/mL of 
Ampicillin (Sigma-Aldrich) followed by the extraction of the plasmid. The plasmids were then sent for 
automatic DNA Sequencing (Stabvida, Costa Caparica, Portugal) to confirm the introduction of each 
mutation. All these steps are in detail described in the section of appendices (Appendix 1: 1-3). 
 
2.2.3. Cloning into pLVX-Puro 
The inserts from each of the above pCDNA constructs were subcloned into pLVX-puro in order 
to generate stable cell lines. The constructs of eGFP/IVS4_5/wt; eGFP/IVS4_5/711+3A>G/flag; and 
eGFP/IVS4_5/711+5G>A/flag were cloned into pLVX-Puro using In-Fusion® HD Cloning Kit 
(Clonetch), and the constructs eGFP/IVS4_5/711+1G>T/flag; and eGFP/IVS4_5/711+3A>T/flag were 
cloned into pLVX-Puro using T4 ligase (ThermoFisher Scientific). Then lentiviral particles were 
produced by human cells and thus create stable cell lines. 
The cDNAs of the constructs were amplified through PCR reactions from the 
pcDNA5/FRT/eGFP/CFTR/IVS4art/IVS5/FLAG with wt and the different mutants, creating 15bp 
extensions with XhoI local restriction sites in both C- and N- terminal (eGFP/IVS4_5/WT; 711+3A>G; 
and 711+5G>A), and creating 15bp extensions with XmaI local restriction in N- terminus and SpeI local 
restriction in C- terminus (eGFP/IVS4_5/711+1G>T; and 711+3A>T) with primers described in table 
2.1. 
 
Table 2.1: List f primers used to amplify cDNA to clone into pLV-Puro. 
Name  Sequence 5’→3’ Amplified 
inserts 













Separately, 3µg of the cDNAs resulting from amplification with XmaI and SpeI primers were 
mixed with 3U SpeI (NZYTech) and 3U XmaI (ThermoFisher Scientific), 1X NZYbuffer U (10 mM 
Tris-HCl, pH 7.4, 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 500 μg/mL BSA, 50% (v/v) glycerol) and 
deionized water to make up the 20µl total reaction. This mixture was then incubated for 3h at 37ºC, 
followed by enzyme inactivation for 20min at 65ºC. 
5µg of pLVX-Puro were linearized using 5U of XhoI (NEB) restriction enzyme mixed with 1X 
NEBbuffer 3.1 (100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 100μg/ml BSA, pH 7.9) and deionized 
water to make up the 25µl total reaction. The reaction was then incubated for 3h at 37ºC, followed by 
enzyme inactivation for 20min at 80ºC, to create ends equal to the XhoI primers extensions, used to 
amplify the cDNAs of eGFP/IVS4_5/WT; 711+3A>G; and 711+5G>A, allowing recombination 
between the vector and the construct. 3 µg of pLVX-Puro was linearized using 3U of XmaI 
(ThermoFisher Scientific) and 3U of XbaI (NZYTech) mixed with 1X NZYbuffer U (10 mM Tris-HCl, 
pH 7.4, 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 500 μg/mL BSA, 50% (v/v) glycerol) and deionized 
water to make up the 20µl total reaction. . The reaction was then incubated 3h at 37ºC, followed by 
enzyme inactivation 20min at 65ºC, to create compatible ends of XmaI and SpeI primers extensions, 
used to amplify the cDNAs of eGFP/IVS4_5/711+1G>T; and 711+3A>T, allowing the ligation between 
the construct and vector. It is important to highlight that XbaI and SpeI generate compatible ends. 
The linearized vector, as well as the cDNAs extended, were spin-column purified using the 
NzyGelPure kit (NZYTech). The In-Fusion cloning was performed mixing 2µl of the enzyme, 200ng of 
cDNA extended, 50ng of linearized vector and nuclease water free up to 20µl, and let it react 15mi at 
50ºC. The ligation reaction was performed mixing 1U of T4 ligase (ThermoFisher Scientific), 213ng of 
cDNA extended and purified, 50ng of linearized vector and nuclease water free up to 20µl, and let it 
react 10min at 22ºC. 
10 µl of the infusion product or the ligation product were then used for bacteria transformation 
as described in Appendix 1: 3. 
‘Colony PCR’ was used to confirm the insertion of the construct into the pLVX. After confirming 
the insertion, the recombinant plasmid was extracted from the positive colonies using NZYMiniprep kit 
(NZYTech, MB010) as described previously in Appendix 1: 3, and the recombinant plasmid was then 
digested with specific restriction enzymes EcoRI (ThermoFisher scientific) to confirm the correct 
insertion of the gene into the vector. If it was correct, the recombinant plasmids were sent for sequencing 
in StabVida. 
After confirming the correct insertion of the insert into pLVX-Puro, the new lentiviral vector was 
used to produce lentiviral particles to transduce CFBE cells. 
 
2.2.4. Production of lentiviral particles 
Lentiviral particles with pLVX/eGFP/IVS4_5/mut/flag or pLVX/eGFP/IVS4_5/WT/flag were 
produced in Human Embryonic Kidney 293T (HEK 293T) cells. 
The cells were seeded at density 5x105 per well on a 6well plate, in Minimum Essential Medium 
Eagle with L-Glutamine (EMEM, Biowhittaker®) supplemented with 10% of Fetal Bovine Serum (FBS, 
GIBCO Life Technologies) and incubated 24h at 37ºC and 5% CO2. The day after the medium was 
changed 3h before the transfection. 
The cells were transfected using Calcium phosphate transfection which involves mixing DNA 
with calcium Cl- in a buffered saline/phosphate solution to generate calcium-phosphate-DNA co-
precipitate, which is then dispersed onto the cultured cells. Calcium phosphate facilitates the binding of 
the condensed DNA in the coprecipitate to the cell surface, and the DNA enters the cell by endocytosis. 
5µg of pLVX (with the desired construct – WT or Mut); 5µg of packaging plasmid pCMV-
dR8.74.psPAX2 and 2.5µg of enveloping plasmid VsV-G/pMD2.G were mixed 1/10 of TE (1mM tris-




incubated for 5 minutes. After that  250µl of HBS (50mM HEPES; 280mM NaCl; 1.5mM Na2HPO4) 
were added to another tube and while vortexing, the previous mixture was added dropwise and then 
incubated for 30 min. Afterwards, the mixture was added to the cells. 
The cells transfected were incubated for 24h at 37ºC, 5% CO2. The medium was then changed 
to EMEM supplemented with 10% FBS to remove the transfection reagent, and the cells were incubated 
for more 42 hours at 37ºC, 5%CO2. 
The lentiviral media were harvested, and the packaging cells were discarded. The lentiviral 
media were immediately used to transduce cystic fibrosis bronchial epithelial (CFBE 41o for short 
CFBE) cells or were stored at -80ºC for further use. 
 
 
2.2.5. Generation of stably transduced cells: lentiviral infection 
CFBE parental cells were plated in a 6 well plate at a concentration of 3x105 cells per well in 2 
ml of EMEM supplemented with 10% FBS a day before of infection with lentiviral media harvested 
from HEK 293T cells and were incubated at 37ºC, 5% CO2. 
The cells were infected with 1ml of lentiviral media and 1ml of EMEM supplemented with 10% 
FBS with 8µg/ml of Polybrene (Hexadimethrine bromide, Sigma-Aldrich) infection enhancer. The plate 
was centrifuged at 220rpm for 1h at 25ºC and then incubated for 24h at 37ºC, 5% CO2. The medium 
was then changed 24 hours after the transfection to EMEM supplemented with 10% FBS. 42 hours post 
infection the media was changed to EMEM supplemented with 10% FBS and 2.5µg/ml of Puromycin, 
which selected the infected cells and killed the non-infected cells. Afterwards, the media was replaced 
24 hours after the first selection with increased concentration of Puromycin (5µg/ml). The medium was 
then changed every 48 hours, and the cells were kept in culture at 37ºC, 5%CO2. 
To analyse the expression of the desired proteins in the stably transduced cells we performed 
biochemical analysis as described in section 2.4. 
The cells were then sorted by flow cytometry to achieve a homogeneous expression of the 
protein. 
 
2.3. Cell culture 
 The characterization of the splicing mutations was made in different cell types and different 
conditions. 
 
2.3.1. Cell lines and culture conditions 
Human Embryonic Kidney 293T (HEK 293T) parental cells were used for transient 
transfections and to produce wt and the mutants (711+1G>T, 711+3A>T, 711´3A>G and 711+5G>A) 
lentiviral particles. These cells were cultured in EMEM supplemented with 10% of FBS. 
Human Embryonic Kidney293 Flp-In (HEK293 Flp-In) parental cells (Invitrogen, Carlsbad, 
CA) were used for stable transfections and were cultured in EMEM supplemented with 10%, selection 
antibiotic Zeocin 100µg/ml (Sigma-Aldrich, St. Louis, MO) before stable transfections and Hygromycin 
after transfections. The Flp-In system allows insertion of the construct in only a single integrated FLP 
recombination target (FRT) site. 
CFBE parental cells, were cultured in EMEM supplemented with 10% FBS. These immortalised 
cells were developed from bronchial epithelial cells from an F508del-CFTR homozygous CF patient 
and did not express endogenous CFTR because it loses the expression with passages. 
All cell lines were maintained at 37ºC in a humidified atmosphere of 5% (v/v) CO2. All cells 






2.3.2. Transient transfections 
HEK293T cells were submitted to liposomal transfection. The liposomal transfection, 
commonly known as lipofection, is based on the ability of cationic lipidic to form unilamellar liposomes, 
which adsorb nucleic acids molecules to their surface and are capable of being internalised by the cells. 
We used Lipofectamine 2000 (Invitrogen) to transiently transfect HEK 293T cells with each pcDNA5 
minigene  
For that 5x105 cells were grown in a 12-well plate 24 hours before the transfection, and 60%-
80% of confluence was desired for transfection. Lipofectamine 2000 (3µl) and 1µg of DNA (pCDNA5 
plasmids with the different constructs) were separately incubated for 5min in 50µl of OPTIMEM 
(Invitrogen), then mixed and allowed to incubate for 15min at RT. The mixture was then added to the 
cells in EMEM without FBS. 
The cells were incubated for 48 hours at 37ºC in 5% CO2, and the RNA and protein were 
extracted to perform RT-PCR, qPCR and Western blot, respectively as described Appendix 1: 1, 2 and 
4 and in this section in 2.5.1, respectively. 
 
2.3.3. Stable transfections in HEK Flp In cells 
Lipofectamine 2000 was used to stably transfect HEK Flp In cell. A vector containing the flipase 
that allow the directed recombination, pOG44, was cotransfected with each desired constructs 
(pCDNA5/FRT/eGFP/IVS4_5/WT or mut/flag) in proportion 3:1 for a total 2µg of DNA, cell selection 
started 48h after transfection by changing the medium to a medium supplemented with 100µg 
Hygromycin B. 
   
2.3.4. Treatment with an AON 
The AON was synthesized by Integrated DNA Technologies, Inc. (IDT, Leuven, Belgium). The 
AON was designed 20 base pairs of distance from the first nucleotide of IVS5 with the following 
sequence: mA* mT* mC* mT* mT* mT* mT* mA* mG* mG* mC* mA* mC* mT* mA* mT* mT* 
mG* mT* mT*. The letter ‘m’ represents an O-methyl modification at the second position of a sugar 
residue, and the asterisk represents a phosphorothioate modification of the backbone. This AON was 
used to transiently transfect cells by Lipofectamine 2000 (Invitrogen). 
48h after transfections mRNA was extracted to perform semi-quantitative and quantitative 
analysis by RT-PCR and qRT-PCR, respectively as described in the appendix section. Biochemical 
analysis were also performed by Western blot and Immunofluorescence to characterize the impact of 
splicing mutations under study. 
 
2.4. Biochemical 
2.4.1. Western Blot 
Cells were washed twice with cold PBS and lysed with sample buffer (1.5% (w/v) SDS; 0.01% 
(w/v) bromophenol blue; 5% (v/v) glycerol; 0.05 dithiothreitol (DTT); 0.095 M Tris, pH 6.8). DNA was 
sheared using benzonase 25U/mL (Sigma-Aldrich) in the presence of 2.5 mM of MgCl2. 
Total protein was quantified using the Bradford assay. Briefly, 10µl of the protein extract was 
added to 990µl of BioRad Protein Assay Reagent (Bio-Rad, 500-0006EDU) diluted in water 
(200µl:800µl), incubated for 5min. The absorbance was measured at 595nm using the 
spectrophotometer (Jasco V-560 UV/Vis spectrophotometer). A regression equation for protein 
concentration was determined using bovine serum albumin (BSA) as a standard protein.  
25µg of protein were loaded on each lane for SDS-polyacrylamide gel electrophoresis (PAGE) 
on 7% separating and 4% stacking gels, and run at 100 V for three hours in a 1X running buffer (25mM 




Polyvinylidene (PVDF) membranes (Millipore) at 400mA for 1.5h in a 1X transfer buffer (25mM Tris, 
192 mM Glycine; pH 8.3, Bio-Rad). 
After the transfer, the membrane was blocked 5% (w/v), non-fat milk in phosphate buffered 
saline (PBS, NaCl 137 mM; KCl 2.7mM; KH2PO4 1.5mM; Na2HPO4 6.5mM, pH 7.4) containing 
0.1%(v/v) Tween (PBS-T) for 1h. The membranes were then probed overnight at 4ºC with primary 
antibodies (596 anti-CFTR mice (1:3000 (BD Transduction Laboratories®) and anti-calnexin mouse 
(BD Transduction Laboratories®) - as a loading control) diluted in 5% (w/v) skimmed milk in PBS-T. 
The membrane was washed three times during 10 min in PBS-T, followed by incubation for one hour 
at Room Temperature(RT) with horseradish peroxidase-conjugated secondary anti-mouse IgG antibody 
(BIO-RAD, goat, 1:5000) in 5% (w/v) skimmed milk-PBS-T and washed another three times during 10 
min with PBS-T. 
Chemiluminescent detection was performed using Chemidoc XRS+ analyser (BIO-RAD), and 
the signal was detected with the Clarity Western ECL substrate (BIO-RAD). Finally, the quantification 




Cells were grown on coverslips in 24-well plates or 8well- Lab-Tek (Sigma-Aldrich) coated 
with 0.001% (w/v) poly-L-lysine (Sigma) to reach 40-60% confluence was reached. 
48hours after transient transfections the cells were washed once with PBS++ (PBS with 
components described in 2.4.1 enriched with 0.7mM of CaCl and 1.1 mM of MgCl2) and incubated with 
mouse anti-flag (Sigma-Aldrich) diluted in PBS++ (1:500) supplemented with 1% (w/v) BSA for 1h at 
4ºC. Afterwards, the cells were rinsed three times with PBS++ and fixed with 4% (w/v) 
Paraformaldehyde (PFA) for 20 min at 4ºC. The cells were then washed three times and incubated with 
a rabbit anti-mouse Cy5 secondary antibody (Life Technologies) in PBS++ (1:500) supplemented with 
1% (w/v) of BSA, one hour at RT. After, the cells were washed three times with PBS and incubated one 
hour in the dark with Hoechst 33342 Fluorescent Stain Life (Life Technologies). The coverslips were 
then mounted on glass slides with Vectashield mounting medium (Vector Laboratories) and sealed. 
Immunofluorescence staining was observed in the Leica DMI 6000B fluorescence microscope, 
which was also used to acquire the images. 
 
2.5. Statistical analysis 
Results are expressed as means ± S.E.M for n observations. Students t-test (GraphPad Prism 
software) for paired and unpaired samples was used as appropriate. Differences were considered 















Section III: Results and Discussion 
3.1. Analysis of Patients 
3.1.1. Patients’ screen studies 
This study was carried out in order to determine whether patients with non-CF respiratory 
diseases have at least one mutation in the CFTR gene. Previous studies have shown that patients with, 
CB/AVD,79 asthma80, disseminated bronchiectasis (DB) and idiopathic pancreatitis with unknown 
etiopathology81,82,83 have at least one CFTR mutation. However, there are also some studies showing 
that the incidence of CFTR mutations in patients with these non-CF respiratory diseases,84 is not 
different from that in the general population,85 thus being contradictory. This study will help to clarify 
these contradictory findings. 
Herein, we tested the occurrence of the 9 most common Portuguese CFTR mutations (outlined 
in Table 3.1)  in non-CF respiratory diseases Portuguese patients. 
  










3272-26 A-G 1.01% 
 
For that purpose, gDNA samples were obtained from 249 individuals including (see Table 3.2): 
1) patients with non-CF respiratory diseases (136); 2) patients with CF or with suspicion of a CF 
diagnosis (30); 3) CF carriers (32); and 4) a control group of 51 healthy individuals with no respiratory 
phenotype. These gDNA samples were screened for the above mutations. Samples from the above 2-4 
groups were included in this study as they were used to validate the pattern of the bands in the ARMS 
and Tetra ARMS PCRs used to determine each patient genotype (see Methods, section 2.1). In addition, 
they will be included in further studies aimed to correlate the occurrence of CFTR mutations with the 
severity of respiratory diseases and with the CFTR-mediated ionic transport. Whenever there was no 
clear genotype identified,  samples were sent for sequencing to confirm the mutation(s).  
The results revealed that 66 (26.5%) individuals had at least one CFTR allele mutated We were 
able to find only 7 out of the 9 most common Portuguese CFTR mutations described in Table 3.3, 
namely: F508del, 3272-26A>G, G542X, R334W, G576A, A561E and R1066C. However, we were also 
able to identify other 7 mutations that were not included in our cohort, namely, I148N, G85E, P205S, 
Q1100P, F1052V, V332Q and 3171del C. From the 14 different mutations that we found, F508del was 
the most common, and it was present in 62% of individuals with at least one mutation, and 14.6% of 
these individuals were homozygous for this mutation. 
Looking into non-CF sub-group with respiratory diseases, the DB patients presented the highest 








3.1.2. Genotype-clinical status Correlation 
It is important to refer that asthma, COPD and DB are also present in some CF patients who are 
characterized by pancreatic exocrine dysfunction, increased sweat electrolyte81, however, herein the 
patients with asthma, COPD and DB did not have any clinical manifestation which would be suggestive 
of a CF diagnosis. 
Among the 249 individuals, 136 had non-CF respiratory diseases namely: DB- 31; COPD- 51; 
and asthma- 54. In this group, we identified the mutations G542X and F508del  and a polymorphism 
G576A in 7 individuals (1 mutation in each individual).   
We observed a variation regarding the incidence of mutated alleles for different pathologies 
within this group of individuals with non-CF respiratory diseases. Accordingly, the highest incidence 
was observed in COPD patients, with 4.9% of mutated alleles, followed by DB with 3.2% of mutated 
alleles (Table 3.2). The lowest incidence of CFTR mutations was observed among the patients with 
asthma, with only 0.9% of mutated alleles. Not surprisingly the frequency of CFTR alleles with 
mutations is higher in CF patients group (91.7%) than in the other groups.  
 











% of alleles 
with 
mutations 
Asthma 54 1 1 0.9% 
DB 31 2 2 3.2% 
COPD 51 4 5 4.9% 
CF 30 28 55 91.7% 
CF carrier 32 31 31 48.4% 
Healthy control 51 0 0 0.0% 
 
A more detailed analysis of the mutations identified and the patient’s genotypes showed that 
The COPD group had the highest incidence of mutated alleles, in which 5 mutated alleles were found 
in 4 individuals and the F508del mutation was again the most common mutation (Table 3.2). A particular 
case was a 52-year old female with COPD who presented one severe mutation in one allele, the G542X 
mutation and one polymorphism, G576A in the other allele. This patient had two negative sweat tests 
and 79% FEV1 (Forced Expiratory volume in one second) and no digestive disease. The G576A 
polymorphism was not found in CF patients, only in CF carriers and COPD patients. In the other two 
respiratory diseases (asthma and DB), only F508del was found. Despite the G576A being described as 
a sequence variation, it can have some effect giving rise to another clinical status such as COPD, thus 
indicating that polymorphisms can also be involved in the etiopathogenesis of at least some cases of 
COPD. Stating that for future studies it is important to include polymorphisms in the cohort of mutations. 
In fact, in one study of incidence of mutations in Italian patients with DB has identified three rare DNA 
polymorphisms, and one of these three was the G576A polymorphism.81 
All CFTR mutations identified here are CF-causing disease except G576A, described as a 
polymorphism in the CFTR database,87 but its influence is under study because this variation is 
associated with several respiratory disorders.88 In CF it has been shown that the G576A polymorphism 
can cause disease when in complex allele with the R668C mutation.89,90   
In this study, more seven mutations were found when some samples were sent for sequencing, 
but interestingly these mutations were not found in patients non-CF respiratory disease (Table 3.3). 




mutation, where asparagine replaces isoleucine in position 148 of the exon 4 is not frequent among CF 
patients, and its severity is unknown,87 but it has been described in one CF Portuguese patient in complex 
allele with 6 repetitions of 5T  in intron 8 (IVS8-6(5T)).91 The other mutations have been described in 
the Hispanic population,92Brazilian (Porto Alegre),93 Spanish,94 and Palestine residents.95 
In this study, some mutations did not show the same incidence as in the reference table. Some 
examples are the A561E and the 3272-26 A>G mutations. The A561E mutation, in which glutamic acid 
replaces alanine at position 561 of the CFTR polypeptide had the smallest incidence, being present in 
3% of the individuals with at least one mutation and 0.8% in overall individuals. This mutation was first 
described in a male nine years old Portuguese patient with moderate lung disease, but pancreatic 
insufficiency and is described as a second widespread mutation in Portugal present in 3% of the overall 
population, where so far four patients were homozygous for this mutation.41,96 The 3272-26 A>G was 
the second more frequent mutation in this study present in 8 patients where one was homozygous for 
the mutation. This mutation was first described in a compound heterozygous with the severe mutation 
W846X, but the patient presented a very mild phenotype, with moderate pulmonary disease and was 
pancreatic sufficient. This mutation occurs in intron 17a creating an alternative splice acceptor site that 
produces an aberrant transcript that includes 25 nucleotides from intron 17a, causing a frameshift leading 
to a premature stop codon.41,97  
Looking only at the results from CF patients analysed in this study, they are in agreement with 
results found in a retrospective study of CF patients in Portugal,91 nevertheless, our study includes other 
groups and not exclusively CF patients, so it can explain the differences in incidence and mutations 

































Table 3.3: Association between the number of mutations identified and Genotypes of CFTR found among each 
group analysed, CF patients (CF), patients with other respiratory diseases (Asthma, DB and COPD), CF carriers and 
healthy controls individuals. 
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In this study, 7 out of 136 individuals with non-CF respiratory diseases had mutations in at least 
one allele. Moreover, in 51 healthy control individuals, nobody had mutations in the CFTR gene, and 
the incidence of carries among Portuguese is 1 in 25 individual, so, it can be accepted that some of the 
most common Portuguese mutations can have some liability in other respiratory diseases. In our study, 
COPD has the highest CFTR mutations incidence, and asthma had the lowest. However, studies by other 
authors where the incidence of CFTR gene mutations and unclassified variants in COPD, DB and asthma 
in children and adults were investigated, it was found that asthma had the highest incidence of CFTR 
mutations and COPD had the lowest incidence,98,99. In a Greek study including patients with COPD, DB 
and asthma it was found some CFTR mutations 98 and any of these mutations were found in our study. 
This disagreement regarding the mutations could be because in our study we only searched for the most 
common Portuguese mutations and in the Greek population study, the screen was performed in all 27 
exons of the CFTR gene. Other studies revealed that congenital mutations in the CFTR gene do not 
enhance the probability of having CFTR dysfunction in patients with COPD84,100 and chronic 
bronchitis85, however, in this study, we have shown that CFTR mutations can have an involvement in 









3.2. Study of splicing mutations in cellular systems 
3.2.1. Generation of the models to study splicing mutations in IVS5 
The second part of this project was to characterize the impact of four mutations located in the 
same splicing consensus, the 711+3A>T, which was first described in a Spanish family101 and we also 
identified it in a Portuguese patient,102 the 711+1G>T, first found in a Canadian family in compound 
heterozygosity with the 621+1G>T splicing mutation,103 the 711+3A>G, first described in two families 
of Albanian origin104 and the 711+5G>A which has also been previously identified in a Italian family.105 
During the screening of mutations in samples of patients with the nine reactions technique 
developed in our laboratory102 and gDNA sequencing, one novel splicing mutation was identified, the 
711+3A>T. 
Herein, we aimed to characterize the impact of the above mutations (each position showed in 
Fig.3.1) at the mRNA and protein levels. For that, we generated cellular models that enabled us to study 
the splicing defects caused by these mutations. 
 
 
                          
Figure 3.1: Schematic representation of the splicing mutations located in same splicing consensus. These mutations 
are located in the 5´´ splice site of intron 5. 
 
A minigene approach was chosen to explore the impact of all these four mutations. So, using a 
minigene containing wt-CFTR cDNA with artificial intron 4 between exon 4 and exon 5 and intron 5 
between exon 5 and exon 6a that already existed in the lab, 
pcDNA5/FRT/eGFP/CFTR/IVS4art/IVS5/Flag, we generated each splicing mutant by site-directed 
mutagenesis (see Methods). 
These five minigenes were then used to transiently transfect both HEK 293T cells and CFBE 
cells. It was hard to generate stable HEK FLP In cells with these minigenes, due to an interference in 
the Hygromycin B coding sequence which was not allowing the survivor of cells when hygromycin was 
added in the media, as outlined in the methods (2.4.3). We then cloned the insert from pcDNA5 into 
PLVX-puro, a lentiviral vector to generate CFBE cells stably expressing each four constructs for further 
comparisons and characterization (this is under process and is not completely done). So, the results 
shown in this work were obtained in Cells transiently expressing pcDNA minigene. 
 
3.2.2. Impact of the splicing mutations at the mRNA and protein levels 
RT-PCR and qPCR: mRNA level  
The impact of the splicing mutations was studied at the mRNA level, and for that purpose, HEK 
293T cells and CFBE cells were transiently transfected with each minigene,  
Firstly, the transcripts obtained from HEK293T cells transiently expressing each minigene were 
semi-quantified by RT-PCR. Primers that amplify the CFTR cDNA from exon 3 to exon 6a were used, 
and it was observed a strong band in wt-CFTR minigene, corresponding to the normal inclusion of exon 
5 and no detectable alternative band (Fig.3.2). However, in all four mutations an alternative lower band 
was detected, corresponding to the transcripts with total skipping of exon 5 (Fig. 3.2) and a wt transcript 
was also detected. Although this analysis was semi-quantitative, it was possible to observe that the 




intense for mutants with the longer the distance from the canonical site. Accordingly, the 711+1G>T 
construct had no detectable wt transcripts. 
It was shown that the skipping of exon 5 does not allow the occurrence of a premature stop 
codon because the joining of the exon 4 and exon 6a is in-frame.106 
These data validated the experimental system and recapitulated the CFTR IVS4/5 splicing in 
patients, thus providing a good model for further studies. 




                                
 
Figure 3.2: Characterization of CFTR transcripts of HEK 293T cells expressing the wt and all four mutants minigene 
by RT-PCR. The transcripts from HEK293T cells expressing wt or 711+1G>T minigene presented only one detectable band 
with different molecular weight (a), for each minigene, being more weighted the wt transcripts with the inclusion of exon 5 
and the mutants with the lowest size corresponding to the exon 5 exclusion, as shown in the lower panel (b). The set of primers 
used for this characterization are shown in upper panel (b). Cells expressing the 711+3A>T, 711+3A>G and 711+5G>A 
minigene, presented two bands: one corresponding to wt transcripts, and the other one corresponding to aberrant transcripts 
with no exon 5. 
 
The transcripts were then quantified by quantitative RT-PCR (qRT-PCR), and it revealed 
differences in abundance of WT transcripts among all mutations as previously observed in the semi-
quantitative analysis (Fig. 3.3). However, in the quantification analysis, samples from cells expressing 
the wt minigene also had detectable levels of transcripts with no exon 5 (~5%) and those from cells 
expressing the 711+1G>T mutation minigene had a few wt transcripts (3%) – as shown in Fig. 3.3, that 
was not detectable by semi-quantitative RT-PCR. Cells expressing the 711+3A>T minigene seem to 
have the highest amount of wt transcripts when compared to the cells expressing the other three 
mutations in the study. Interestingly, we detected a diminished amount of wt transcripts caused by the 
711+5G>A mutation, 7.4%±5. In our lab, another mutation in the +5 position (2789+5G>A) in intron 
14b has been previously studied, and it was observed that mutants expressing the 2789+5G>A  minigene 
have 56% of wt transcripts.57 
The difference between the two techniques is that the qPCR technique is more sensitive and can 
detect lower expression levels of transcripts compared to the RT-PCR technique. These data illustrate 
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Figure 3.3: Quantitative analysis of CFTR transcripts with exon 5 inclusion (WT transcripts) and exon 5 exclusion 
(del ex5 transcripts) from HEK 293T cells transiently expressing different minigenes (WT and mutants). 2way ANOVA 
Multiple comparisons were used to compare wt and del ex5 transcripts among the various splicing mutations and WT minigene. 
The statistical differences are expressed with multiple P values, being P=0.015 (*), P=0.0015 (**), P<0.0001 (****) and P≈0.9 
(ns). Data are expressed as mean ± SEM of three independent experiments. 
 
Results obtained in transient transfections of HEK 293T cells were then confirmed using mRNA 
extracted directly from native tissues of individuals with this mutation. For that purpose, cDNA was 
synthetized from mRNA extracted from small pieces of lung of individuals with no mutation (control) 
and from organoids (a 3D-structure grown from stem cells extracted from rectal biopsies of individuals) 
from two patients with the 711+1G>T/F508del genotype. 
Interestingly, in individuals with the 711+1G>T/F508del genotype, ~50% of the transcripts are 
aberrant and the other ~50% are normally spliced transcripts, suggesting that the normally spliced 
transcripts result from the F508del allele and the transcripts with no exon 5 result from the 711+1G>T 
allele (Fig. 3.4). These data show that in these individuals the mutation 711+1G>T originates only 
aberrant transcripts. In parallel, no aberrant transcripts were detected in the healthy control. 
 
             
Figure 3.4: Quantitative RT-PCR analysis of CFTR transcripts (normal and aberrant transcript with no exon 5) from 
individuals with cystic fibrosis (711+1G>T/F508del) and healthy control. Multiple t-tests were used to see the differences 
between the amount of wt and transcripts with no exon 5 (del ex5 transcript).  The amount of wt transcripts and aberrant 
transcripts (del ex5 transcript) are not statistically different in CF patient (ns) with P=0.028, and they are statistically different 
(**) in healthy control, with P<0.0001. Data are expressed as mean ± SEM of four independent experiments for the 




In summary, the results obtained by qRT-PCR and RT-PCR suggested that the 711+1G>T is a 
severe splicing mutation, while the 711+3A>T and 711+3A>G splicing mutations could be considered 
milder mutations because of the amount of wt transcripts produced in cells expressing the splicing 
mutations, since it has been shown that patients with 5% of normal CFTR transcripts have a significantly 
milder disease.73 The 711+5G>A mutation is described in the CFTR database, as causing PI when 
combined with other mutation that also causes pancreatic insufficiency,87showing the severity of this 
mutation. 
The quantification of transcripts obtained in CFBE cells transiently expressing the WT and all 
splicing minigenes, also showed that all mutations strongly reduced the levels of correctly spliced 
transcripts (data not shown). Additionally, it revealed that the 711+1G>T did not originate any correctly 
spliced transcripts, giving slightly different results from that obtained in HEK 293T cells. These data 
suggest that different cell types can process splicing differently, being thus important to confirm all 
results obtained by the minigene approach by direct mRNA analysis in patient’s samples.71 
All these mutations alter the WT donor site,107thus leading to aberrant splicing. However, the 
mechanisms of the splicing disruption in all these mutations are not entirely understood. 
Using the Human Splicing Finder (HSF) software to explore the elements that regulate the 
splicing, it was possible to identify three splicing elements just downstream of the invariant G (GT- at 
the 5’ end of the intron or the donor splice site), namely, 2 intronic splicing enhancer elements (ISE) 
and one intronic splicing silencer element (ISS) in between the two ISE (represented in Fig. 3.5), that 
are in balance when the mutations are not there,108 and the occurrence of mutations in positions where 




Figure 3.5: Schematic representation of splicing elements located in the 5’ss consensus, that can be disrupted if any 
mutation occurs. The splicing mutations located in the same splicing consensus disrupt the local bind of splicing elements, such 
as Intronic splicing silencer (ISS) a local binding of heterogeneous Ribonucleoproteins (hnRNP), that repress the splicing and 
may cause the exon skipping and Intronic splicing enhancer (ISE), a local binding of serin-arginin rich proteins (SR) wich 
enhance the splicing and may promote the exon inclusion. Additionally, the local binding of Small Ribonucleoproteins ( 
U1snRNP), which recognise the splice site, to begin the splicing process is in the same sequence. 
 
Protein analysis 
The impact of the four splicing mutations was also studied at the protein level in CFBE cells 
and HEK cells transiently transfected with each minigene. To this end, total protein was harvested 48h 
post-transfection, and CFTR protein was analysed by WB. Results from CFBE cells transiently 
expressing each minigene revealed that cells transfected with wt minigenes exhibited two bands, a fully 
mature glycosylated CFTR band C (170kDa), a core-glycosylated fraction band B (140kDa)109 and the 
127 kDa band A (Fig. 3.6). 110,111  
In both cell lines (CFBE and HEK), the protein resulting from the four splicing mutations 
presented two lower molecular weight bands, namely: one band between 140 and 170KDa and another 
lower band of less than 140 kDa (Fig 3.6). These results can suggest that the upper band (between 140 




90bp of the exon 5) and the other lower band corresponds to a core-glycosylated form of this shorter 
protein. 
However, the lack of exon 5, corresponds to the loss of only 30 aminoacids (30aa), and as the 
average molecular weight of an aminoacid is 100Da, 30aa will correspond to 3KDa. The 7% 
polyacrylamide gel used here is not sufficient to show this small difference. But, if these mutations 
produce a protein with different conformation, the protein can migrate differently in the gel.                       
 
 Figure 3.6: Analysis of the protein obtained from CFBE cells transiently transfected with wt, 711+1G>T, 711+3A>T, 
711+3A>G and 711+5G>A minigenes. In the left panel, a representative membrane from WB shows the migration pattern of 
protein obtained from transiently transfected cells, with different molecular weights. In the right panel, the quantification 
protein of gels (n=3) indicates the quantification of the total amount of CFTR in wt and all mutants. The comparison between 
wt and each mutant were performed using an unpaired t-test, and the statistical differences are shown as (**) when 
0.001<P<0.01, (*) when P=0.02 and (ns) when the data are not statistically different. Data are expressed as mean ± SEM of 
three independent experiments. 
 
In fact, one study using a construction of CFTR cDNA, with deletion of exon 5, revealed that 
cells transfected with this Δexon5 CFTR expressed only a core-glycosylated form of CFTR with 
140KDa. It also showed that neither incubation at lower temperature (26º), nor stimulation of HEK 293T 
cells with forskolin cause rescue in glycosylation and processing of the Δexon5 CFTR protein, 
indicating that this mutation was not processed properly.109 
The first intracellular loop (aminoacid 139-194) connects transmembrane segments II and III, 
and 30 of the residues in this loop are encoded by exon 5.112 It was shown that deleting 30 aminoacids 
from the first intracellular loop of CFTR affects both processing and function of the CFTR Cl- 
channel.109 So most likely our mutants have a similar defect. To confirm this, further studies should 
include the functional characterization of the protein to determine the channel activity. 
The minigenes are double-tagged to allow to verify the localization of the protein in all four 
mutants. These minigenes have eGFP in the N-terminus to see the total amount of the protein and flag 
in the 4th extracellular loop to see only the protein located in the PM. With this strategy was possible to 
observe that the protein of cells expressing the wt mini-gene is located in the PM, but in all four mutants 
the eGFP fluorescence is decreased and that the protein is mislocalized in the PM (Fig. 3.7). 
These data would corroborate previous results obtained 21 years ago, which showed that the 
skipping of exon 5 caused misprocessing of the CFTR protein, that this aberrant protein does not reach 
the membrane and that it is retained primarily in the intracellular membrane.109 
Altogether these data validated the use of minigene constructs to study the effect of splicing 
mutations and showed that the mutations produce truncated proteins that may affect either their 






Figure 3.7: Characterization of localization of the CFTR protein of  HEK 293T cells expressing the wt and all four 
mutants minigene by immunofluorescence. The CFTR protein in HEK293T cells expressing three splicing mutations is not 
localized in the membrane. 
 
3.2.3. Effect of the AON on all splicing mutations 
It was shown that the four splicing mutations in the same splicing consensus (711+1G>T, 
+3A>T, +3A>G and +5G>A) cause full skipping of exon 5, and reduce the amount of correctly spliced 
transcripts to about 95%.  
After studying the impact of four mutations located in the same splicing consensus, we aimed 
to explore whether we were able to correct the splicing defect caused by the mutations using an AON. 
Only one AON was designed to cover all the mutations as they are in the same splicing consensus. 
For that, an AON was designed 20 bases downstream from the donor splice site (Fig. 3.8), and 
it was transiently co-transfected with each minigene in HEK 293T cells followed by the analysis of the 
splicing correction at the mRNA level by semi-quantitative and quantitative PCR. Data from both 
analyses showed that the same AON could correct all four mutations at the mRNA level, with major 
correction seen in 711+3A>G (as shown in figure 3.9 and 3.10). 
 
 
 Figure 3.8: Schematic representation of the position of AON in IVS5. 
 
Quantification of transcripts showed that the same AON efficiently corrected the splicing 
mutations in the range of 10-65%, being efficient the longer the distance from the canonical site, being 
more efficient to correct the 711+3A>T than 711+3A>G. In each mutation, the AON corrected in the 
different proportion. Despite being no statistical difference for the mutation 711+1G>T, the AON 
promoted the exon inclusion from 2% to 12%. For the other mutations it efficiently corrected, namely, 






 Figure 3.9: Correction of alternative splicing accessed by RT-PCR. Representative gel from the electrophoretic 
analysis showing the enhancement of inclusion of exon 5 (upper band) in cells co-transfected with AON and each mutant 
minigene. 
 
       
 Figure 3.10: Correction of alternative splicing accessed by qPCR. Real-time qPCR showing that the same AON 
corrects alternative splicing caused by all four mutations in the range of to 10-65% at increased efficiencies the longer the 
distance to the canonical splice site, and, for position +3. It being more efficient to correct the A>T than A>G : 711+1 G>T < 
711+3 A>G < 711+3 A>T < 711+5 G>A. The differences between the mock and treated cells expressing each minigene were 
accessed by unpaired t-test, and the differences between the wt and all mutants were accessed by 2way ANOVA. The 
differences were statistically considered when P<0.05. Data are expressed as mean ± SEM of three independent experiments. 
 
To access whether the AON increases the total CFTR protein, we performed WB with lysates 
from HEK 293T cells co-expressing the AON and each mutant, and it was observed that the protein 
increased after the AON treatment, however, only in mutant 711+3A>G the differences were statistically 
different (Fig.3.11). A non-specific AON was used as a negative control (referred here as scramble), 
and it was observed that this scrambled AON did not have any effect in correcting the mutants.These 
data suggest that the AON effect is sequence specific for intron 5.  










Figure 3.11: Correction of four splicing mutations in the same splicing consensus by AON strategy at the protein 
level (a-c). Representative western blot analysis of wt and four splicing (711+1G>T, 711+3A>T, 711+3A>G and 711+5G>A) 
mutations. Cells expressing the wt minigene were submitted to all treatments used in cells expressing the mutants minigenes 
to evaluate the toxicity and malicious effect of the treatments. (d) Quantification of total protein from WB analysis from two 
independent experiments showing that the same AON could enhance the total amount of protein of all mutants with exception 
in mutant 711+3A>T. The differences between each mutant before and after treatment were assessed using t-test and were 
considered only statistically different when P<0.05 (*). Data are expressed as mean ± SEM of two independent experiments. 
 
All four splicing mutations may promote misprocessing of the CFTR protein, leading to a 
mislocalization of protein at the surface of the cell. To see whether the AON could promote the proper 
processing and traffic of the CFTR protein to the plasma membrane, HEK 293T cells transiently 
expressing each minigene treated and not treated with AON were used for immunofluorescence (Fig. 
3.12). The AON promoted the expression of the flag in the mutants, which we could not detect in the 
non-treated cells.  
Altogether, these data with the mRNA and protein analyses indicate that the same AON can 
correct mutations localized in the same splicing consensus site, suggesting that that patients with one of 









                        
Figure 3.12: Correction of four splicing mutations in the same splicing consensus by AON strategy at the protein 
level accessed by immunofluorescence. Representative images of AON treated and non-treated cells. Quantification of CFTR 
at the PM. The CFTR at the PM was normalized to total expression levels (eGFP fluorescence). Data are the mean of three 
different experiments and shown as mean ± SEM. 
 
Herein, we have hypothesized how all four mutations impair the correct splicing and that the 
occurrence of these mutations disrupt the fine-tuned balance of factors that regulate splice site selection, 
such as ISE and ISS elements (Fig. 3.13). Furthermore, it is well known that the U1 small RNA (U1 
snRNA), the first component of the spliceosome that guide the recognition of the donor splice site 
interacts with the first six nucleotides of the intron,108 thus suggesting that the mutations also impair the 
base pair of U1snRNA and the donor site.  
 
 Figure 3.13: Schematic representation of the cis-acting splicing regulatory elements and trans-acting 
splicing factors. These cis-acting elements can be classified as intronic splicing silencer (ISS), intronic splicing 
enhancer (ISE), exonic splicing silencer (ESS) and exonic splicing enhancer (ESE) based on their location and 
activity. In general ISS and ESS recruit splicing factors (heterogeneous nuclear ribonucleoproteins - hnRNPs) that 
inhibit the recognition of nearby splice sites, while ISE and ESE recruit splicing factors (serine-arginine rich proteins 
family - SR) that inhibit the recognition of nearby splice sites, thus inhibiting and promoting the splicing, respectively. 
The dashed arrow represents the first step of the spliceosome assembly and coloured letters represent the consensus 
motifs of the splice sites. Splicing at a particular site can be activated or repressed when these auxiliary proteins bind 
nearby enhancer or silencer regions—to recruit or inhibit assembly/stability of spliceosomal components, 
respectively. downstream of the splice site, in the IVS5 the sequence is rich in ISS’s, as it bears 14 inhibitor elements 
until the position +32. Indeed, the AON designed here totally covers 6 of these ISS and represses the binding of 
heterogeneous nuclear ribonucleoproteins A1 (hnRNP A1 – which usually promote exon exclusion) (lower scheme). 
Adapted from113 
 
However, this is just a speculative argument which does not explain why exon five is excluded 
in mutation 711+1G>T, since a novel mutation (in the same position), the 711+1G>A mutation was 




It was also found that the same AON could correct all these four mutations with different 
efficiencies, but the question now is, how does it correct them? One explanation may be that downstream 
of the splice site, the sequence is rich in ISS’s, as it bears 14 inhibitor elements until the position +32,107. 
Indeed, the AON designed here totally covers 6 of these ISS, and represses the binding of heterogeneous 
nuclear ribonucleoproteins A1 (hnRNP A1 – which usually promote exon exclusion)115. 
This suggests that these ISSs within the first 32 nucleotides of IVS5 may play an important role 
in the exon 5 exclusion. Further studies should be conducted to confirm these hypotheses and find out 













Section IV: Conclusions and future perspectives 
The first part of this MSc work consisted in studies of the possible involvement of the most 
common commonly found among Portuguese population in causing non-CF respiratory diseases, and 
we conclude that F508del was the most common mutation in all individuals together, even among 
carriers, with the incidence of 62%. The second most common mutation was the 3272-26 A>G mutation 
extensively described in Portugal, but not included in the CF database.Two mutations (G542X and 
F508del) and one sequence variation (G576A) were found among non-CF patients with respiratory 
diseases, in which COPD patients had the highest incidence (4.9%) of mutated alleles and asthma 
patients had the lowest incidence (0.9%) of the mutated alleles. Furthermore, patients with asthma and 
COPD presented only F508del mutation.  
In this study, only the most common mutations that occur in Portugal were screened, and with 
this, some important or novel mutations can be missed, and mainly for the non-CF individuals with 
respiratory diseases, where rare mutations can be found. It would be beneficial to conduct additional 
CFTR genetic analysis in a larger cohort of mutations to rule out the CFTR as a contributor of other 
respiratory diseases. 
The second part was the characterization of the impact of 711+1G>T, 711+3A>T, 711A>G 
and 711+5G>A mutations located in the same splice consensus and their correction with an AON 
approach. For that end, a splicing reporter minigene already constructed in our lab was used, and it was 
concluded that these mutations lead to total in-frame skipping of exon 5 with a more pronounced 
decrease in the inclusion of exon 5, the closer the mutation is to the splice site. The skipping of exon 5 
leads to the mislocalization of the CFTR protein in the PM. The unique AON constructed for this study 
was able to correct all mutations, being more efficient in correcting mutations that lie further from the 
canonical splice site. These data suggest that all patients with one of these four mutations can benefit 
with this AON and it can help to improve the quality of life of these patients.  
Neither the splicing elements involved in skipping of exon 5 nor the mechanism of action of the 
AON used in this study are not entirely understood, further studies are necessary such as the multiple 
deletions of intron 5 and 4 to search for the most important splicing elements involved in the skipping 
of exon 5 and to see how the same AON could promote such results in all four mutations, even in the 
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Section VI: Appendices 
Appendix 1 – Introduction, Material and Methods  
 
  
  Figure 1S: schematic representation of splicing process. U1 binds to the 5’ splice site (5´-ss) by 
complementarity and U2 binds to the branch point. The triple snRNPs (U4, U5 and U6) complex moves-in to 
associate with the assembling spliceosome. Then, the U4 leaves the complex, allowing the replacement of U1 by 
U6 that interacts with U2 to bring the branch point into proximity to the 5´-ss. At this point, the first 
transesterification reaction cleaves the 5'-ss of the intron of the downstream exon and attaches it to the branch 
point. U5 then brings the 3'-ss of the upstream exon and 5'-ss of the downstream exon into proximity with each 
other, allowing a second transesterification reaction that cleaves the 3'-ss of the upstream exon. 
 
1. RNA extraction 
Using the NucleoSpin® RNA kit from MACHERY-NAGEL (MN) (Duren, Germany), cells and 
tissues are lysed by incubation in a solution containing significant amounts of chaotropic ions. This lysis 
buffer immediately inactivates RNases, which are present in virtually all biological materials, creates an 
appropriate binding condition which favour adsorption of RNA to the silica membrane. The remaining 
contaminating DNA that also bound to the silica membrane is removed by a rDnase solution, applied 
directly onto the membrane during the preparation. Simple washing steps with two different buffers 
remove salts, metabolites and macromolecular cellular components. Pure RNA is finally eluted under 
low ionic strength conditions with RNase-free water. 
Following extraction, the RNA was quantified using Nanodrop 200 spectrophotometer, and purity 
was assessed by the A260/280 ratio. Only RNA samples with a ratio above 2.0 were deemed acceptable. 
The extracted samples were stored at -80ºC. 
 
2. cDNA synthesis 
cDNA from the previously extracted RNA was synthesised with NZY M-MuLV REVERSE 
TRANSCRIPTASE kit. The enzyme from this kit is a recombinant form of the Reverse Transcriptase 
from the Moloney Murine Leukemia Virus (M-MuLV) purified from Escherichia coli. This enzyme 




length cDNA even for long mRNA, using random priming. Furthermore, it gives high yields of first 
strand cDNA up to 7Kb. 
1µg of RNA was incubated with 50ng of a Random hexamer, 0.5mM of dNTP Mix and RNase 
water free up to 17µl for 5min at 65ºC to promote the denaturation of the secondary structure of the 
RNA facilitating the binding of the oligo-dTs to the poly-A (poly adenosine) strand of mRNAs and 
enhancing reverse transcription yields. Then the pre-mix containing RNA, random hexamer, dNTP Mix 
and water was chilled on ice, followed by addition of 2µl of 10x Reaction Buffer (500mM Tris-HCl, pH 
8.3, 750mM KCl, 30mM MgCl2 and 100mM DTT), 1µl of Nzy Ribonuclease Inhibitor and 200 units of 
Nzy M-MuLV Reverse Transcriptase. Afterwards, this mixture was incubated for 10 min a 25ºC, then 
for 50min at 37ºC and inactivated for 15min at 70ºC. 
The resulting cDNA strand was used for reverse transcription- polymerase chain reaction (RT-PCR) 
or were stored at -20ºC. 
 
 
3. Transformation of competent bacteria and extraction of plasmids 
200µl of competent bacteria made in our lab were incubated with the hydrolysis product (described 
in 2.2.2) for 30 min on ice, followed by heat-shock for 1.5min at 42ºC, incubation for 2 min in ice, and 
then incubation in antibiotic-free LB medium for one hour at 37ºC at 220rpm. Bacteria were then 
centrifuged for 2 min at 6000g. The supernatant was discarded and the pellet was resuspended in the 
remaining supernatant medium. This suspension was then plated onto LB agar (Sigma-Aldrich) 
supplemented with 100µg of Ampicillin and incubated overnight at 37ºC. 
The recombinant bacteria were then grown in LB medium (Sigma-Aldrich) supplemented with 
100µg of ampicillin and incubated overnight at 37ºC, where then the plasmids were extracted. 
The plasmids were extracted using NZYMiniprep kit (NZYTech) following the manufacturers’ 
instructions, and the concentration was measured as described in this section (1). Afterwards, to confirm 
the introduction of each pontual mutation, the extracted plasmids were sent to StabVida for sequencing, 
with the primers described in Table 5. 
 
4. qPCR: quantitative analysis 
mRNA expression was analysed using quantitative real-time RT-PCR (qRT-PCR). cDNA from lung 
tissue and cells were lysed to assess the mRNA expression of CFTR gene. 
qPCR was performed in 96 well plates (Bio-Rad Laboratories) with Evagreen reaction mixture (Bio-
Rad Laboratories) using Cx96 real-time PCR machine. The primers for the distinction of wt and 
alternative transcript were requested and selected by Dr Luka Clark using ExonMine database.116  The 
primers utilized in qPCR amplify across exon boundaries between exon 4 and exon 5  to minimise 
potential background amplification of products from genomic DNA. 
5 µl of the template cDNA (diluted 1:5), 250 nM of each forward and reverse primer (outlined in 
this section – Table 3), and 1x Evagreen PCR reaction mixture per well was used to prepare the qPCR 
reaction. The optimized cycle conditions for Evagreen was used: 10 seconds (sec) at 95 oC and 30 sec 
at 60oC, these steps were repeated 40 cycles.  To confirm amplification of specific product melting curve 
was performed with a temperature gradient from 65 to 95ºC. 
Relative abundance of mRNA was measured using samples run in triplicate the Bio-Rad CFX 
Manager 2.0 software (Bio-Rad, 1845000). 
Transcript levels of the CFTR gene were calculated by normalizing to an endogenous gene, 
Adenylate cyclase-associated protein 1 (Cap-1). The mean threshold cycle (CT) of the targets genes was 
calculated by subtracting the mean CT of the control gene, ΔCT. Then, the mean ΔCT was calculated 
for a chosen condition, control condition. This mean ΔCT was calculated from several replicates, and it 




to the chosen condition.  The fold difference in gene expression was calculated by the relative 
quantification method using the mathematical equation 2–ΔΔCT 
 
Table 1: Description of all primers used for complete sequencing of CFTR 
Name Orientation Sequence 5’→3’ 
T7 Foward  
Ex3F Foward GGA TAG AGA GCT GGC 
TTC 
CF5ZR* Foward TTG TAC CAG CTC ACT 
ACC T 
Ex5F Foward CTC CTT TCC AAC AAC 
CTG AAC 
B3R Foward AAT GTA ACA GCC TTC 
TGG GAG 
C1R Foward GTG GAG GTC AAC GAG 
CAA GA 
D2R Foward GCA AAC TTG ACT GAA 
CTG GA 
E1R Foward AGA TTC TCC AAA GAT 
ATA GC  
Ex18F Foward AAC TCC AGC ATA GAT 
GTG G   
Ex22F Foward AGC AGT TGA TGT GCT 
TGG C   
*mainly used for confirmation of the pontual mutations on IVS5. 
 
Table 2: Description of mutagenic primers for splicing mutations introducing 
Name Orientation Sequence 5’→3’ 
711+1G>T.F Foward CCT GAA CAA ATT TGA TGA ATT ATG TAC CTA TTG 
711+1G>T.R Reverse CAATAGGTACATAATTCATCAAATTTGTTCAGG 
711+3A>G.F Foward CTG AAC AAA TTT GAT GAA GTG TGT ACC TAT TGA TTT 
AAT C 
711+3A>G.R Reverse GATTAAATCAATAGGTACACACTTCATCAAATTTGTTCAG 
711+3A>T.F Foward CTG AAC AAA TTT GAT GAA GTT TGT ACC TAT TGA TTT 
AAT C 
711+3A>T.R Reverse GATTAAATCAATAGGTACAAACTTCATCAAATTTGTTCAG 
711+5G>A.F Foward GAACAAATTTGATGAAGTATATACCTATTGATTTAATC 














Table 3: Description of primers used in qPCR technique 
Name Orientation Sequence 5’→3’ Function 
Cap-1.F Foward ATGCACCGTGGGTATGCAG Amplify 
endogenous 
gene 
Cap-1.R Reverse AAGCAGCGAGTCAAATGCCT 
Ex5Rev Reverse TCAGGTTGTTGGAAAGGAGAC Amplify only wt 
transcripts 
Ex4/6Rev Reverse CCAATGCAAGTCCCTTCTTATAAATC Amplify only 
transcripts with 
no exon 5 
Ex4Fwd 
common 
Foward TGACCCGGATAACAAGGAGG Common  
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